11 research outputs found
Pancreatic function in control and MSG-treated groups as measured by (A) insulin levels at 1, 3, 6, and 9 months (mean ± SEM) and (B) oral glucose tolerance test (OGTT) at 9 months(mean ± SD).
<p>Pancreatic function in control and MSG-treated groups as measured by (A) insulin levels at 1, 3, 6, and 9 months (mean ± SEM) and (B) oral glucose tolerance test (OGTT) at 9 months(mean ± SD).</p
Islet size (um<sup>2</sup>) distribution in control and MSG-treated groups at 1, 3, 6, and 9 months.
<p>Islet size (um<sup>2</sup>) distribution in control and MSG-treated groups at 1, 3, 6, and 9 months.</p
Representative histology (left) and prevalence (right) of islets hemorrhage/hemosiderin deposits in the control and MSG-treated group at 1, 3, 6, and 9 months (x400).
<p>Representative histology (left) and prevalence (right) of islets hemorrhage/hemosiderin deposits in the control and MSG-treated group at 1, 3, 6, and 9 months (x400).</p
Representative immunohistochemistry (left) and prevalence (right) of insulin staining in control versus MSG-treated groups at 1, 3, 6, and 9 months (x400).
<p>* <i>P</i><0.05.</p
Body weight (panel A), food (panel B) and water (panel C) intake in the control and MSG-treated groups at 1, 3, 6, and 9 months of study.
<p>* <i>P</i><0.05.</p
Islet density in control and MSG-treated groups at 1, 3, 6, and 9 months.
<p>Islet density in control and MSG-treated groups at 1, 3, 6, and 9 months.</p
CaP-index in 9 months control and MSG-treated rats.
<p>CaP-index in 9 months control and MSG-treated rats.</p
Renal interstitial fibrosis in 9 months MSG-treated animals (100x).
<p>Renal interstitial fibrosis in 9 months MSG-treated animals (100x).</p
Mean food intake (a), water intake (b), and growth curve (c) in 10 rats from the MSG-treated and control groups at different time-points over 9 months.
<p>Mean food intake (a), water intake (b), and growth curve (c) in 10 rats from the MSG-treated and control groups at different time-points over 9 months.</p